This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Jan;59(1):386-7.

doi: 10.1046/j.1523-1755.2001.00508.x.

Criteria for calcimimetic agent in the treatment of more severe secondary hyperparathyroidism

D Pavlovic, H T Brzac

PMID: 11135101
DOI: 10.1046/j.1523-1755.2001.00508.x

Free article

Comment

Criteria for calcimimetic agent in the treatment of more severe secondary hyperparathyroidism

D Pavlovic et al. Kidney Int. 2001 Jan.

Free article

. 2001 Jan;59(1):386-7.

doi: 10.1046/j.1523-1755.2001.00508.x.

Authors

D Pavlovic, H T Brzac

PMID: 11135101
DOI: 10.1046/j.1523-1755.2001.00508.x

No abstract available

PubMed Disclaimer

Comment on

The hyperparathyroidism of chronic renal failure: a disorder of growth.
Parfitt AM. Parfitt AM. Kidney Int. 1997 Jul;52(1):3-9. doi: 10.1038/ki.1997.297. Kidney Int. 1997. PMID: 9211340 Review. No abstract available.
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. Goodman WG, et al. Kidney Int. 2000 Jul;58(1):436-45. doi: 10.1046/j.1523-1755.2000.00183.x. Kidney Int. 2000. PMID: 10886592 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.